Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2013 - 2026)

Ocular Therapeutix's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 30.78% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $4.6 million (up 20.36% YoY), while the FY2025 annual figure was $4.3 million, up 14.18% from the prior year.
• Depreciation & Amortization (CF) was $1.3 million for Q1 2026 at Ocular Therapeutix, up from $1.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q1 2026 to a low of $483000.0 in Q1 2023.
• Historically, Depreciation & Amortization (CF) has averaged $852176.5 across 5 years, with a median of $951000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) dropped 14.31% in 2022, then surged 95.11% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $491000.0 in 2022, then jumped by 95.11% to $958000.0 in 2023, then slipped by 0.73% to $951000.0 in 2024, then surged by 31.13% to $1.2 million in 2025, then gained by 2.89% to $1.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.